APPLICATION
NDA050574
TYPE
NDA
ORIGINAL APPROVAL
1983-11-14
LATEST ACTION
2026-05-29
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription
Products
SANDIMMUNE · ReferencePrescription
CYCLOSPORINE 100MG/ML · SOLUTION · ORAL
Approval history
2016-07-14Manufacturing (CMC) · Supplement 52 · priorityAP
2014-01-22Manufacturing (CMC) · Supplement 49 · priorityAP
2002-06-14Manufacturing (CMC) · Supplement 32 · priorityAP
2002-04-12Manufacturing (CMC) · Supplement 33 · priorityAP
2002-02-22Manufacturing (CMC) · Supplement 30 · priorityAP
2002-01-16Manufacturing (CMC) · Supplement 31 · priorityAP
2001-11-16Manufacturing (CMC) · Supplement 28 · priorityAP
2000-10-04Labeling · Supplement 25 · standardAP
1999-12-21Labeling · Supplement 26 · standardAP
1999-05-13Manufacturing (CMC) · Supplement 24 · priorityAP
1998-10-20Manufacturing (CMC) · Supplement 23 · priorityAP
1998-07-27Manufacturing (CMC) · Supplement 22 · priorityAP
1998-03-30Manufacturing (CMC) · Supplement 20 · priorityAP
1998-01-30Manufacturing (CMC) · Supplement 21 · priorityAP
1996-08-09Labeling · Supplement 18 · standardAP
1996-03-22Manufacturing (CMC) · Supplement 19 · priorityAP
1995-11-21Labeling · Supplement 17 · standardAP
1995-04-28Manufacturing (CMC) · Supplement 16 · priorityAP
1995-03-07Manufacturing (CMC) · Supplement 14 · priorityAP
1994-11-10Labeling · Supplement 15 · standardAP
1994-05-19Manufacturing (CMC) · Supplement 13 · priorityAP
1994-05-09Manufacturing (CMC) · Supplement 12 · priorityAP
1994-05-09Manufacturing (CMC) · Supplement 11 · priorityAP
1993-03-19Manufacturing (CMC) · Supplement 10 · priorityAP
1993-02-24Manufacturing (CMC) · Supplement 4 · priorityAP
1993-02-16Manufacturing (CMC) · Supplement 3 · priorityAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.